Diabetic macular edema (DME) is the most common cause of vision loss in patients with
diabetic retinopathy with an increasing prevalence tied to the global epidemic in type 2 …

Ocular anti-vascular endothelial growth factor (VEGF) therapy represents one of the most
significant advances in modern medicine. The introduction and widespread use of ocular …

Objective The objective is to formulate clinical practice guidelines for the treatment of
diabetes in older adults. Conclusions Diabetes, particularly type 2, is becoming more …

Background: Diabetic retinopathy is a leading cause of visual impairment in working-age
adults worldwide. Duration of diabetes is a major risk factor associated with the development …

Importance Anti–vascular endothelial growth factor (VEGF) medicines have revolutionized
diabetic macular edema (DME) treatment. A recent randomized clinical trial comparing anti …

Purpose: We assessed differences in compliance and adherence (lateness of patients,
visual acuity, reasons for abstaining) between patients with diabetic macular edema (DME) …

Purpose To provide evidence-based recommendations for diabetic macular edema (DME)
management based on updated information from publications on DME treatment modalities …

Purpose To assess the efficacy and safety of intravitreal bevacizumab (IVB) compared with
ranibizumab (IVR) in the treatment of macular oedema due to branch retinal vein occlusion …

Importance While diabetes prevalence among US adults has increased in recent decades,
few studies document trends in diabetes-related eye disease. Objective To examine 10-year …

Background The increasing incidence of medical retinal diseases has created capacity
issues across UK. In this study, we describe the implementation and outcomes of virtual …